Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395785 | 0.91 | KDM4E (0.46) | MAPK1TSHRKDM4EMAPTCA12 | |
| SCHEMBL15725731 | 0.89 | CYP3A4 (0.45) | MAPK1TSHRKDM4EMAPTCA12 | |
| SCHEMBL1820328 | 0.87 | LMNA (0.43) | MAPK1TSHRKDM4EMAPTCA12 | |
| SCHEMBL28876343 | 0.83 | CYP3A4 (0.44) | MAPK1TSHRCA12CA1CA2 | |
| SCHEMBL17838501 | 0.82 | CA1 (0.45) | MAPK1TSHRKDM4EMAPTCA12 | |
| SCHEMBL1819165 | 0.81 | CA12 (0.52) | MAPK1TSHRKDM4ECA12CA1 | |
| SCHEMBL18131839 | 0.81 | CYP3A4 (0.53) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL16665282 | 0.81 | CYP3A4 (0.41) | MAPK1TSHRKDM4EMAPTCYP3A4 | |
| SCHEMBL29179289 | 0.81 | MRGPRX4 (0.51) | MAPK1KDM4EHPGDLMNAMEN1 | |
| SCHEMBL31728795 | 0.79 | KDM4E (0.43) | MAPK1TSHRKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| CN-111278823-B | Heterocyclic compounds as fibroblast growth factor receptor inhibitors | 上海新契博生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | TERNS PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3986405-A1 | COMPOUNDS FOR INHIBITING FGFR4 | Terns Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114144176-A | Compounds for inhibiting FGFR4 | 拓臻制药公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | NOVARTIS AG | 2010-09-16 | — | — | US | disclosed |
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2044036-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008747-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008747-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2008-01-17 | — | — | WO | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPK1 1699/4885TSHR 3036/4885KDM4E 2775/4885 |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | FGFR3, ERBB2, ERBB4 | MAPK1 56/4885TSHR 4043/4885KDM4E 402/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPK1 4884/4885TSHR 2837/4885KDM4E 3792/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPK1 1699/4885TSHR 3036/4885KDM4E 2775/4885 |
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | MAPK1 91/4885TSHR 3028/4885KDM4E 954/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | MAPK1 1419/4885TSHR 3801/4885KDM4E 1870/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | MAPK1 1699/4885TSHR 3036/4885KDM4E 2775/4885 |
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | FGFR4, FGFR1, FGFR3 | MAPK1 859/4885TSHR 3410/4885KDM4E 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.